CD274 and neoplasm: This approach not only induces cuproptosis but also increases PD-L1 expression, transforming “cold” tumors into “hot” tumors that respond to immunotherapy, significantly inhibiting tumor growth and activating a systemic anti-tumor immune response.326 Related therapeutic agents include T-HCN@CuMS,469 Cel-Cu NP,379 ES@CuO,327 Ce6@Cu NPs,470 ES-Cu-MOF,471 Cu@CDCN,472 mCGYL-LOx,337 AuTPyP,333 PDA-DTC/Cu,473 Cu-THBQ/AX,383 MACuS,474 CuO NPs,475 ZCA NSs,476 Cu2-xSe@cMOF,477 CSTD-Cu(II)@DSF,465and CuPEs@PApt,478 among others.